Skip to content
MARKETS / NASDAQ / BTAIQ
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

BioXcel Therapeutics, Inc. BTAIQ

9 fiscal years on record · USD · FY2025 reported · SEC filings only
$642,000
▼ 71.7% YoY
$-69.9M
$-57.6M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth
USD 642,000.00
Revenue, FY2025 · full 9-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.6 · Net income -69.9
-80M-160M201720182019202020212022202320242025
Compound annual growth
+19.6%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
·
Operating margin Net margin
FY2025 · Operating -7860.0%
-20000%-40000%201720182019202020212022202320242025
ROE
FY2023 · ROE -1766.9%
-500%-1000%-1500%201720182019202020212022202320242025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.

Return on equity has no reading this year — return on capital employed, just below, still does: -1422%.

Cash & shareholders
·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -57.6
-80M201720182019202020212022202320242025
Net buybacks $M Dividends $M
FY2020 · Dividends · · Net buybacks -246.8
-100M-200M2020

Total assetsUSD 44.9M
EquityUSD -95.5M
CashUSD 28.4M
Gross debtUSD 109.6M
Net debtUSD 81.2M
Current ratio0.83×

Equity was zero or negative — liabilities equaled or exceeded assets. No ratio is shown.

The 9-year record
9 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020201920182017
Revenue $B0.00.00.00.0·····
Operating income $B−0.1−0.1−0.2−0.2−0.1−0.1−0.0−0.0−0.0
EBITDA $B−0.1−0.1−0.2−0.2−0.1−0.1−0.0−0.0−0.0
Income tax $B0.00.00.0······
Net income $B−0.1−0.1−0.2−0.2−0.1−0.1−0.0−0.0−0.0
Free cash flow $B−0.1−0.1−0.2−0.1−0.1−0.1−0.0−0.0·
EPS, diluted $−5.73−23.51−98.33−5.92−4.05−3.79−2.02−1.32−0.47
Dividend / sh $·········
Payout %·········
ROE %··−1766.9−111.1−49.9−70.4−100.2−101.7·
Shares out B0.020.000.030.030.030.020.020.020.01

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 36 reconciliationsAUDITED

Reconciled in 9 of 19 fiscal years. 20 checks were skipped: the balance sheet is not tagged before 2017. 15 checks were skipped: revenue is not tagged before 2022. 10 checks were skipped: EPS is not tagged before 2017.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2017

Share this section

Download image